|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Physiology (2002), 544.1, p. 1
© Copyright 2002 The Physiological Society
DOI: 10.1113/jphysiol.2002.027151
Email: d.j.beech{at}leeds.ac.uk
Unravelling the mechanisms of noradrenaline's vasoconstrictor action is a fascinating business, and an important example of the rich texture of signalling within smooth muscle cells. Noradrenaline's stimulation of
1-adrenoceptors sets off complex signalling cascades that act to initiate and maintain vascular smooth muscle contraction. One early discovery was that noradrenaline releases Ca2+ from intracellular stores. Whether this is a graded, all-or-nothing or oscillatory response, the stores must at some stage refill. This can occur partly by uptake of cytosolic Ca2+ but, because released Ca2+ is extruded from the cell, Ca2+ replenishment from the extracellular fluid is also necessary. Voltage-gated Ca2+ channels can contribute, but vascular smooth muscle cells - like other cell types - would also seem to have specialised Ca2+ channels for this function. Twenty-one years ago in The Journal of Physiology, Casteels & Droogmans published results obtained using 45Ca2+ as a tracer. Depletion of intracellular stores stimulated the rate of 45Ca2+ uptake from the extracellular solution. The pathway appeared to be tightly coupled to stores because the Ca2+ uptake failed to cause contraction. It was resistant to conventional Ca2+ antagonists and inhibited by K+-induced depolarisation. Manganese ions blocked the pathway. These data were the first suggesting the existence of a store-operated channel (SOC) that opens to allow Ca2+ entry when Ca2+ stores deplete.
The evidence for SOCs in vascular smooth muscle is good. Blockade of Ca2+ reuptake into stores by inhibitors (e.g. cyclopiazonic acid) of the store's Ca2+-ATPase (SERCA) or chelation of Ca2+ leaking from stores by BAPTA both cause store depletion while circumventing complexities of
-adrenoceptor-mediated signalling. Both also activate Ca2+-permeable non-selective cationic channels in the plasma membrane of aortic and portal vein smooth muscle cells (Trepakova et al. 2000; Albert & Large, 2002a). The portal vein channels differ from those in aorta, for example showing greater Ca2+-selectivity, but neither is as Ca2+-selective as the calcium-release-activated Ca2+ (CRAC) channels of lymphocytes. Nevertheless, both vascular channels are coupled to store depletion. SERCA's fundamental role in intracellular Ca2+ handling and in the superficial buffer barrier of vascular smooth muscle can complicate experiments with SERCA inhibitors, as can background Ca2+-flux pathways. The use of manganese flux as an indicator of SOC activity may be undermined by manganese block of SOCs. But, by-and-large, such experiments have supported the existence of SOCs in vascular smooth muscle. Further evidence has also emerged. The SOCs of aortic myocytes are activated by calcium influx factor (CIF), a substance of unknown chemical identity released from store-depleted - but not control - platelets (Trepakova et al. 2000). There is also TRPC1 protein at the plasma membrane of vascular smooth muscle cells. TRPC1 has sequence homology to voltage-gated ion channel
-subunits. Nine independent laboratories now have data showing it is a functional component of SOCs. A TRPC1 peptide-specific antibody attenuates SOC-mediated Ca2+ entry in vascular smooth muscle (Xu & Beech, 2001). Intriguingly, in platelets, TRPC1 co-immunoprecipitates with inositol trisphosphate receptor, but only when stores are depleted (Rosado & Sage, 2001). Therefore, molecular elements necessary for SOCs are present and active in vascular smooth muscle.
In this issue of The Journal of Physiology, Albert & Large (2002b) report patch-clamp data on the mechanism coupling
1-adrenoceptors to SOCs in portal vein smooth muscle cells. They provide compelling evidence that SOCs can be activated independently of store depletion. In cell-attached patches noradrenaline activates channels that are biophysically very similar to those activated by cyclopiazonic acid - i.e. they both appear to activate the same SOC. Strikingly, SOC activation by noradrenaline, cyclopiazonic acid or BAPTA is prevented by protein kinase C inhibitors. In excised outside-out patches, noradrenaline and protein kinase C activators stimulate SOCs - but cyclopiazonic acid has no effect, as if the store-depletion mechanism is absent. Therefore, although noradrenaline depletes Ca2+ stores it seems it can also activate the portal vein SOCs independently of store-depletion, via a classical phospholipase C-diacylglycerol-protein kinase C pathway. The physiological importance of this effect compared with the store-operated mechanism will need to be worked out, as will the apparent dual role of protein kinase C in the store-independent and -dependent pathways. We can look forward to more intrigue to come.
| Albert, A. P. & Large, W. A. (2002a). Journal of Physiology 538, 717-728. | [Abstract/Full Text] |
| Albert, A. P. & Large, W. A. (2002b).Journal of Physiology 544, 113-125. | [Abstract/Full Text] |
| Casteels, R. & Droogmans, G. (1981).Journal of Physiology 317, 263-279 | [Abstract] |
| Rosado, J. A. & Sage, S. O. (2001).Biochemical Journal 356, 191-198. | [Medline] |
| Trepakova, E. S., Csutora, P., Hunton, D. L., Marchase, R. B., Cohen, R.A. & Bolotina, V. M. (2000). Journal of Biological Chemistry 275, 26158-26163. | [Abstract/Full Text] |
| Xu, S. Z. & Beech, D. J. (2001).Circulation Research 88, 84-87. | [Abstract/Full Text] |
This article has been cited by other articles:
![]() |
K. M. Park, M. Trucillo, N. Serban, R. A. Cohen, and V. M. Bolotina Role of iPLA2 and store-operated channels in agonist-induced Ca2+ influx and constriction in cerebral, mesenteric, and carotid arteries Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1183 - H1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Passmore, A. A. Selyanko, M. Mistry, M. Al-Qatari, S. J. Marsh, E. A. Matthews, A. H. Dickenson, T. A. Brown, S. A. Burbidge, M. Main, et al. KCNQ/M Currents in Sensory Neurons: Significance for Pain Therapy J. Neurosci., August 6, 2003; 23(18): 7227 - 7236. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |